Status:
COMPLETED
PACMAN - PAcing for CardioMyopathies, a EuropeAN Study
Lead Sponsor:
Boston Scientific Corporation
Conditions:
Heart Failure
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to evaluate the benefit of biventricular pacing in patients with heart failure who were receiving optimal pharmacological therapy, and who were either with or without an ...
Detailed Description
Heart Failure is a syndrome that affects millions of patients in Europe with over half a million new cases reported annually. Drug therapy had been the conventional treatment of choice until the emerg...
Eligibility Criteria
Inclusion
- \- NYHA Class III and IV with EF \< 35%; Optimal individual drug therapy in 2 weeks prior to enrollment including ACE inhibitors; beta blockers and diuretics unless not tolerated
Exclusion
- Reduced life expectancy of \< 6 months or candidate for heart transplant within 6 months; chronic/recurrent atrial fibrillation/flutter
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT00180596
Start Date
January 1 2000
End Date
September 1 2005
Last Update
January 6 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Guidant Corporation, , , Belgium
Diegem, Belgium, 1831
2
Medizinische Klinik I, University RWTH Aachen
Aachen, Germany, 52057